Home / Resource Library / Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged >80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged >80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

ASH 2024

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged >80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)